Insmed Inc. (INSM) announced Tuesday morning that its Phase 3 study of ALIS in adult patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium Avium Complex met its primary endpoint.
from RTT - Hot Stocks http://ift.tt/2x6Mjs0
via IFTTT
No comments:
Post a Comment